Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Jones

Showing results (221-230 of 945) with videos related to

Pageof 95
Sort By:
Antimicrobial Agents and Chemotherapy|January 1, 1992
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporinR N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|July 1, 1976
In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolatesR N Jones, P C Fuchs
Diagnostic Microbiology and Infectious Disease|May 1, 1996
The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococciD J Biedenbach, R N Jones
American Journal of Surgery|October 1, 1992
Cefotaxime is extensively used for surgical prophylaxisH S Sader, R N Jones
Antimicrobial Agents and Chemotherapy|February 1, 1990
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinoloneR N Jones, A L Barry
Diagnostic Microbiology and Infectious Disease|March 1, 1983
Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobialsR N Jones, H W Wilson
Journal of Clinical Microbiology|January 1, 1995
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolatesL D Sutton, R N Jones
Antimicrobial Agents and Chemotherapy|February 1, 1993
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneB B Gooding, R N Jones
Antimicrobial Agents and Chemotherapy|December 1, 1993
In vitro activity of DU-6859a, a new fluorocyclopropyl quinoloneS A Marshall, R N Jones
Diagnostic Microbiology and Infectious Disease|November 1, 1993
Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration resultR N Jones, G E Zurenko
Pageof 95

Showing results (221-230 of 945) with videos related to

Sort By:
Pageof 95
Antimicrobial Agents and Chemotherapy|January 1, 1992
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporinR N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|July 1, 1976
In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolatesR N Jones, P C Fuchs
Diagnostic Microbiology and Infectious Disease|May 1, 1996
The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococciD J Biedenbach, R N Jones
American Journal of Surgery|October 1, 1992
Cefotaxime is extensively used for surgical prophylaxisH S Sader, R N Jones
Antimicrobial Agents and Chemotherapy|February 1, 1990
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinoloneR N Jones, A L Barry
Diagnostic Microbiology and Infectious Disease|March 1, 1983
Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobialsR N Jones, H W Wilson
Journal of Clinical Microbiology|January 1, 1995
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolatesL D Sutton, R N Jones
Antimicrobial Agents and Chemotherapy|February 1, 1993
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneB B Gooding, R N Jones
Antimicrobial Agents and Chemotherapy|December 1, 1993
In vitro activity of DU-6859a, a new fluorocyclopropyl quinoloneS A Marshall, R N Jones
Diagnostic Microbiology and Infectious Disease|November 1, 1993
Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration resultR N Jones, G E Zurenko
Pageof 95